Georges Dagher

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Inherited defect in a Na+, K+ -co-transport system in erythrocytes from essential hypertensive patients

Ricardo P. Garay, Georges Dagher, Marie-Gabrielle Pernollet et al. · Nature · 1980 · 275 citations

Medicine, Biochemistry, Physiology +12

Laboratory Distinction between Essential and Secondary Hypertension by Measurement of Erythrocyte Cation Fluxes

Ricardo P. Garay, Jean‐Luc Elghozi, Georges Dagher et al. · New England Journal of Medicine · 1980 · 170 citations

Medicine, Cardiology, Physiology +14

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17